CME Lesson
Lesson 6 – Prescribing Controlled Substances – References and Resources
The following references and resources have been provided by the speakers for additional study.
Addiction: Brain Disease or Just an Excuse for Bad Behavior?
- Ries, RK. (2014) Principles of Addiction Medicine (5th ed.). Chevy Chase, MD: American Society of Addiction Medicine.
- Volkow, N. D., Fowler, J. S., Wang, G.-J. & Swanson, J. M. (2004). Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol. Psychiatry, 9, 557–569. (doi:10.1038/sj.mp.4001507)
Amphetamines and Controlled Substance Schedules
- 'Amphetamines' at Wikipedia.com
- Amphetamine use, etc - drugs.com
Prescribing Opioids and Obvious Pitfalls Thereof
- Principles of Addiction Medicine – Fourth Edition
- Prescription Drug Abuse Crisis: Mississippi Prescribers’ Response – Scott Hambleton MD
- Utah Clinical Guidelines on Prescribing Opioids- Utah Dept. of Health
- Chronic Pain Perspectives – Frontline Medical Communications
- FDA Blueprint for Prescriber Education for ER and LA Analgesics
- Canadian Guideline for Safe and Effective Use of Opioids for CNCP
- Prescribing for Pain – Daniel P. Alford MD/Boston University School of Medicine
- Substance Abuse- A Comprehensive Textbook --- Fourth Edition
Benzodiazepines: Avoiding Pitfalls of Inappropriate Prescribing
- Ries, RK. (2014) Principles of Addiction Medicine (5th ed.). Chevy Chase, MD: American Society of Addiction Medicine.
- Volkow, N. D., Fowler, J. S., Wang, G.-J. & Swanson, J. M. (2004). Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol. Psychiatry, 9, 557–569. (doi:10.1038/sj.mp.4001507)
Pain Management: A Perspective from the Other Side
- Mississippi State Board of Medical Licensure(MSBML)(www.msbml.ms.gov/)
- Federation of State Medical Boards' (FSMB) Model Policy on the Use of Opioid Analgesics in the Treatment of Chronic Pain(www.fsmb.org/)
- Responsible Opioid Prescribing–A Clinician’s Guide (www.fsmb.org/)Scott M. Fishman, MD, Chief of Pain Medicine, University of California, Davis
- US FDA Blueprint for Risk Evaluation and Mitigation Strategy (REMS) for Extended-Release and Long-Acting Opioid Analgesics (www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm163647.htm)
